Improvement of acquired partial lipodystrophy with rosiglitazone despite ongoing complement activation [9]

Rheumatology

Volumn 42, Issue 2, 2003, Pages 393-394

  Walker, U A ^b   Kirschfink, M ^a   Peter, H H ^b  

^a Institute for Immunology   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPSIN; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3D; NEPHRITIC FACTOR; ROSIGLITAZONE;

ADIPOCYTE; ADIPOSE TISSUE; ADULT; ANTHROPOMETRY; BODY FAT; CASE REPORT; CELL DIFFERENTIATION; COMPLEMENT ACTIVATION; DRUG MECHANISM; FEMALE; GLOMERULONEPHRITIS; HUMAN; LABORATORY TEST; LETTER; LIPODYSTROPHY; METABOLIC DISORDER; PRIORITY JOURNAL; SUBCUTANEOUS TISSUE; WEIGHT GAIN;

ADULT; ANTHROPOMETRY; COMPLEMENT ACTIVATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPODYSTROPHY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 0344837917     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keg076     Document Type: Letter

References (8)

1. Mathieson PW, Würzner R, Oliveria DB, Lachmann PJ, Peters DK. Complement-mediated adipocyte lysis by nephritic factor sera. J Exp Med 1993;177:1827-31.
2. Rother U. A new screening test for C3 nephritis factor based on a stable cell bound convertase on sheep erythrocytes. J Immunol Methods 1982;51:101-7.
3. Choy LN, Rosen BS, Spiegelman BM. Adipsin and an endogenous pathway of complement from adipose cells. J Biol Chem 1992;267:12736-41.
4. Mathieson PW, Peters DK. Lipodystrophy in MCGN type II: the clue to links between the adipocyte and the complement system. Nephrol Dial Transplant 1997; 12:1804-6.
5. Weiss L, Rougier N, Blouin J, Kazatchkine MD, Lhotta K, Konig P. Hypocomplementaemia in a newborn caused by transplacental passage of maternal autoantibody with C3 nephritic factor (C3 NeF) activity. Nephrol Dial Transplant 1995;10:2374.
6. Skattum L, Martensson U, Sjoholm AG. Hypocomplementaemia caused by C3 nephritic factors (C3 NeF): clinical findings and the coincidence of C3 NeF type II with anti-Clq autoantibodies. J Intern Med 1997;242:455-64.
7. Gewurz AT, Imherr SM, Strauss S, Gewurz H, Mold C. C3 nephritic factor and hypocomplementaemia in a clinically healthy individual. Clin Exp Immunol 1983;54:253-8.
8. Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000;133:263-74.